A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Summary

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Timeline

Start

2023-07-11

Primary completion

2026-05

Completion

2026-08

Drugs

Indications